JP2018535196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535196A5 JP2018535196A5 JP2018516843A JP2018516843A JP2018535196A5 JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5 JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- heavy chain
- domain
- antibody
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188060.6 | 2015-10-02 | ||
| EP15188060.6A EP3150637A1 (en) | 2015-10-02 | 2015-10-02 | Multispecific antibodies |
| EP16168918 | 2016-05-10 | ||
| EP16168918.7 | 2016-05-10 | ||
| PCT/EP2016/073410 WO2017055539A1 (en) | 2015-10-02 | 2016-09-30 | Multispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535196A JP2018535196A (ja) | 2018-11-29 |
| JP2018535196A5 true JP2018535196A5 (enExample) | 2019-11-07 |
| JP7239320B2 JP7239320B2 (ja) | 2023-03-14 |
Family
ID=57068100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516843A Active JP7239320B2 (ja) | 2015-10-02 | 2016-09-30 | 多重特異性抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20170129962A1 (enExample) |
| EP (1) | EP3356420B1 (enExample) |
| JP (1) | JP7239320B2 (enExample) |
| CN (1) | CN108290958B (enExample) |
| WO (1) | WO2017055539A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価抗原結合タンパク質 |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| ES2788979T3 (es) | 2014-11-14 | 2020-10-23 | Hoffmann La Roche | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| JP6996979B2 (ja) | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3150636A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| EP3589650A1 (en) | 2017-03-02 | 2020-01-08 | Novartis AG | Engineered heterodimeric proteins |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| CA3084398A1 (en) * | 2018-01-15 | 2019-07-18 | I-Mab Biopharma Us Limited | Modified c.kappa. and ch1 domains |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| JP7541930B2 (ja) | 2018-06-29 | 2024-08-29 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ１抗体およびその使用 |
| US20220089722A1 (en) * | 2018-12-29 | 2022-03-24 | Nantong Yichen Biopharma. Co. Ltd. | Heterodimeric fusion protein |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CA3248133A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| EP4493593A1 (en) * | 2022-03-18 | 2025-01-22 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| US20250333484A1 (en) | 2022-04-14 | 2025-10-30 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to ebola virus glycoprotein and their use |
| AU2023268051A1 (en) | 2022-05-13 | 2025-01-02 | BioNTech SE | Rna compositions targeting hiv |
| CA3277013A1 (en) * | 2022-12-14 | 2024-06-20 | Evolveimmune Therapeutics, Inc. | BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE |
| WO2024138151A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| CN121127490A (zh) | 2022-12-28 | 2025-12-12 | 生物技术欧洲股份公司 | 靶向hiv的rna组合物 |
| CN121866336A (zh) | 2023-08-03 | 2026-04-14 | 百欧恩泰欧洲股份公司 | 靶向hiv的rna组合物 |
| EP4754130A2 (en) | 2023-08-03 | 2026-06-10 | BioNTech SE | Rna compositions targeting hiv |
| WO2025098100A1 (en) * | 2023-11-07 | 2025-05-15 | Biomap (Suzhou) Intelligent Technology Limited | Modified polypeptides for heteromultimer |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE102005028778A1 (de) * | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7642282B2 (en) * | 2007-01-19 | 2010-01-05 | Milliken & Company | Whitening agents for cellulosic substrates |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JP2014511836A (ja) | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| KR101261949B1 (ko) * | 2011-05-13 | 2013-05-13 | 현대자동차주식회사 | 촉매유닛 |
| US8901853B2 (en) * | 2012-07-11 | 2014-12-02 | Analog Devices, Inc. | Multi-string LED drive system |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| PL3092251T3 (pl) * | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
-
2016
- 2016-09-30 CN CN201680069598.7A patent/CN108290958B/zh active Active
- 2016-09-30 JP JP2018516843A patent/JP7239320B2/ja active Active
- 2016-09-30 EP EP16775695.6A patent/EP3356420B1/en active Active
- 2016-09-30 WO PCT/EP2016/073410 patent/WO2017055539A1/en not_active Ceased
- 2016-09-30 US US15/281,542 patent/US20170129962A1/en not_active Abandoned
-
2022
- 2022-01-27 US US17/586,455 patent/US20220363771A1/en not_active Abandoned
-
2025
- 2025-05-02 US US19/197,889 patent/US20260201049A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522888A5 (enExample) | ||
| JP2022088627A (ja) | 多重特異性および多機能性分子ならびにその使用 | |
| JP2020122013A5 (enExample) | ||
| JP2023100868A (ja) | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 | |
| JP2022523197A (ja) | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP2022521750A (ja) | カルレティキュリンに結合する多機能性分子およびその使用 | |
| CN112955465A (zh) | 抗tcr抗体分子及其用途 | |
| JP2020023523A5 (enExample) | ||
| WO2020094834A1 (en) | Il2rbeta/common gamma chain antibodies | |
| EP3707162A1 (en) | Il2rbeta/common gamma chain antibodies | |
| JP2019531725A (ja) | ラムダ及びカッパ軽鎖を含む多重特異性抗体分子 | |
| IL269270B (en) | Method and preparations for cellular immunotherapy | |
| JP2019527543A5 (enExample) | ||
| CA3164972A1 (en) | Materials and methods for in vivo biological targeting | |
| JP2019536430A5 (enExample) | ||
| TW201815825A (zh) | 經修飾之抗原結合fab片段及包含其之抗原結合分子 | |
| JP2019530431A5 (enExample) | ||
| JP2018512856A5 (enExample) | ||
| JP2024515591A (ja) | Ｔｃｒに結合する多機能性分子およびその使用 | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2018521691A5 (enExample) | ||
| CN121779568A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| TW202233674A (zh) | 用於調節δγ鏈介導之免疫的組成物及方法 | |
| JP2025536908A (ja) | Ｔｃｒに結合する多機能性分子およびその使用 |